The Saint-Amand-les-Eaux site is relatively recent, as it was created only a decade or so ago. It’s the fruit of a major investment by GSK, which spent €600 million on designing and building a state-of-the-art plant equipped with the latest technology and boasting industry-leading facilities for secondary vaccine production. Our production is on the rise, reaching 130 million doses in 2022, and will continue to grow over the years to come. Our Nord-based site has taken on a predominant role at Group level, as we are one of the two or three largest GSK vaccine-production sites in the world in terms of volume.